Sumitomo Pharma Co., Ltd. operates as a global entity focused on the development, manufacturing, and distribution of a diverse range of products. Its primary offerings include pharmaceutical drugs, food components and additives, and veterinary treatments. The company's reach extends across Japan, North America, China, and various other international markets. The pharmaceutical segment boasts an extensive portfolio addressing numerous medical conditions. This encompasses therapeutic agents for neurological disorders like Parkinson's disease and epilepsy, psychiatric conditions such as depression and atypical psychosis, and metabolic challenges including type 2 diabetes. Sumitomo Pharma also produces medications for cardiovascular diseases (e.g., hypertension, angina pectoris, arrhythmia), urological problems (such as overactive bladder and advanced prostate cancer), and other ailments like uterine fibroids, systemic fungal infections, pruritus, and chronic obstructive pulmonary disease (COPD). Additionally, it develops specialized treatments, including cultured thymus tissue for pediatric congenital athymia, drugs for rare diseases like Fabry disease, and carbapenem antibiotics. Beyond its core pharmaceutical operations, the company provides food-related products, specifically polysaccharides and various seasonings, including soups and bouillons. Its chemical product materials division serves multiple industries by supplying pharmaceutical excipients, ingredients for personal care products, coatings and industrial materials, and electronic materials. The company's veterinary division is dedicated to formulating and distributing medications for both household pets, such as dogs and cats, and a broad spectrum of livestock, including cattle, pigs, poultry, horses, and aquacultured fish. To drive innovation and expand its capabilities, Sumitomo Pharma engages in numerous strategic collaborations. It maintains partnerships with entities like Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. Key agreements also include a joint development initiative with SanBio Company Limited and a collaboration and licensing deal with Otsuka Pharmaceutical Co., Ltd. Furthermore, the company has formed a strategic alliance with Roivant Sciences Ltd. Sumitomo Pharma Co., Ltd. was established in Osaka, Japan, in 1897. The company, formerly known as Sumitomo Dainippon Pharma Co., Ltd., officially changed its name to Sumitomo Pharma Co., Ltd. in April 2022. It operates as a subsidiary of Sumitomo Chemical Company, Limited.
—
Sumitomo Pharma Co., Ltd. operates as a global entity focused on the development, manufacturing, and distribution of a diverse range of products. Its primary offerings include pharmaceutical drugs, food components and additives, and veterinary treatments. The company's reach extends across Japan, North America, China, and various other international markets. The pharmaceutical segment boasts an extensive portfolio addressing numerous medical conditions. This encompasses therapeutic agents for neurological disorders like Parkinson's disease and epilepsy, psychiatric conditions such as depression and atypical psychosis, and metabolic challenges including type 2 diabetes. Sumitomo Pharma also produces medications for cardiovascular diseases (e.g., hypertension, angina pectoris, arrhythmia), urological problems (such as overactive bladder and advanced prostate cancer), and other ailments like uterine fibroids, systemic fungal infections, pruritus, and chronic obstructive pulmonary disease (COPD). Additionally, it develops specialized treatments, including cultured thymus tissue for pediatric congenital athymia, drugs for rare diseases like Fabry disease, and carbapenem antibiotics. Beyond its core pharmaceutical operations, the company provides food-related products, specifically polysaccharides and various seasonings, including soups and bouillons. Its chemical product materials division serves multiple industries by supplying pharmaceutical excipients, ingredients for personal care products, coatings and industrial materials, and electronic materials. The company's veterinary division is dedicated to formulating and distributing medications for both household pets, such as dogs and cats, and a broad spectrum of livestock, including cattle, pigs, poultry, horses, and aquacultured fish. To drive innovation and expand its capabilities, Sumitomo Pharma engages in numerous strategic collaborations. It maintains partnerships with entities like Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. Key agreements also include a joint development initiative with SanBio Company Limited and a collaboration and licensing deal with Otsuka Pharmaceutical Co., Ltd. Furthermore, the company has formed a strategic alliance with Roivant Sciences Ltd. Sumitomo Pharma Co., Ltd. was established in Osaka, Japan, in 1897. The company, formerly known as Sumitomo Dainippon Pharma Co., Ltd., officially changed its name to Sumitomo Pharma Co., Ltd. in April 2022. It operates as a subsidiary of Sumitomo Chemical Company, Limited.
—
Daily adjusted close
Sumitomo Pharma Co., Ltd. operates as a global entity focused on the development, manufacturing, and distribution of a diverse range of products. Its primary offerings include pharmaceutical drugs, food components and additives, and veterinary treatments. The company's reach extends across Japan, North America, China, and various other international markets. The pharmaceutical segment boasts an extensive portfolio addressing numerous medical conditions. This encompasses therapeutic agents for neurological disorders like Parkinson's disease and epilepsy, psychiatric conditions such as depression and atypical psychosis, and metabolic challenges including type 2 diabetes. Sumitomo Pharma also produces medications for cardiovascular diseases (e.g., hypertension, angina pectoris, arrhythmia), urological problems (such as overactive bladder and advanced prostate cancer), and other ailments like uterine fibroids, systemic fungal infections, pruritus, and chronic obstructive pulmonary disease (COPD). Additionally, it develops specialized treatments, including cultured thymus tissue for pediatric congenital athymia, drugs for rare diseases like Fabry disease, and carbapenem antibiotics. Beyond its core pharmaceutical operations, the company provides food-related products, specifically polysaccharides and various seasonings, including soups and bouillons. Its chemical product materials division serves multiple industries by supplying pharmaceutical excipients, ingredients for personal care products, coatings and industrial materials, and electronic materials. The company's veterinary division is dedicated to formulating and distributing medications for both household pets, such as dogs and cats, and a broad spectrum of livestock, including cattle, pigs, poultry, horses, and aquacultured fish. To drive innovation and expand its capabilities, Sumitomo Pharma engages in numerous strategic collaborations. It maintains partnerships with entities like Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. Key agreements also include a joint development initiative with SanBio Company Limited and a collaboration and licensing deal with Otsuka Pharmaceutical Co., Ltd. Furthermore, the company has formed a strategic alliance with Roivant Sciences Ltd. Sumitomo Pharma Co., Ltd. was established in Osaka, Japan, in 1897. The company, formerly known as Sumitomo Dainippon Pharma Co., Ltd., officially changed its name to Sumitomo Pharma Co., Ltd. in April 2022. It operates as a subsidiary of Sumitomo Chemical Company, Limited.